{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:00:35Z","timestamp":1792432835351,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13346-020-00756-x","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T14:02:51Z","timestamp":1586527371000},"page":"1288-1301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Colon targeted bioadhesive pellets of curcumin and cyclosporine for improved management of inflammatory bowel disease"],"prefix":"10.1007","volume":"10","author":[{"given":"Neha","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munira","family":"Momin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"key":"756_CR1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13346-013-0185-4","volume":"4","author":"R Malayandi","year":"2014","unstructured":"Malayandi R, Kondamudi PK, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv Transl Res. 2014;4:187\u2013202.","journal-title":"Drug Deliv Transl Res"},{"key":"756_CR2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s13346-014-0195-x","volume":"4","author":"SK Vemula","year":"2014","unstructured":"Vemula SK, Veerareddy PR, Devadasu VR. Pharmacokinetics of ketorolac tromethamine compression-coated tablets for colon delivery. Drug Deliv Transl Res. 2014;4:310\u20139.","journal-title":"Drug Deliv Transl Res"},{"key":"756_CR3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s13346-018-0512-x","volume":"9","author":"M Sohail","year":"2019","unstructured":"Sohail M, Mudassir, Minhas MU, Khan S, Hussain Z, de Matas M, et al. Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects. Drug Deliv Transl Res. 2019;9:595\u2013614.","journal-title":"Drug Deliv Transl Res"},{"key":"756_CR4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1517\/17425247.5.5.483","volume":"5","author":"SK Jain","year":"2008","unstructured":"Jain SK, Jain A. Target-specific drug release to the colon. Expert Opin Drug Deliv. 2008;5:483\u201398.","journal-title":"Expert Opin Drug Deliv"},{"key":"756_CR5","doi-asserted-by":"crossref","unstructured":"Guo Y, Zong S, Pu Y, Xu B, Zhang T, Wang B. Advances in pharmaceutical strategies enhancing the efficiencies of oral colon-targeted delivery systems in inflammatory bowel disease. Molecules. 2018;23.","DOI":"10.3390\/molecules23071622"},{"key":"756_CR6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2478\/v10007-012-0025-y","volume":"62","author":"J Varshosaz","year":"2012","unstructured":"Varshosaz J, Emami J, Tavakoli N, Minaiyan M, Rahmani N, Dorkoosh F, et al. Colon specific delivery of budesonide based on triple coated pellets: in vitro\/in vivo evaluation. Acta Pharma. 2012;62:341\u201356.","journal-title":"Acta Pharma"},{"key":"756_CR7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jconrel.2018.01.003","volume":"272","author":"S Sharma","year":"2018","unstructured":"Sharma S, Sinha VR. Current pharmaceutical strategies for efficient site specific delivery in inflamed distal intestinal mucosa. J Control Release. 2018;272:97\u2013106.","journal-title":"J Control Release"},{"key":"756_CR8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2012.01.028","volume":"161","author":"E-M Collnot","year":"2012","unstructured":"Collnot E-M, Ali H, Lehr C-M. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012;161:235\u201346.","journal-title":"J Control Release"},{"key":"756_CR9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0975-8453.59516","volume":"1","author":"S Das","year":"2010","unstructured":"Das S, Deshmukh R, Jha A. Role of natural polymers in the development of multiparticulate systems for colon drug targeting. Syst Rev Pharm. 2010;1:79.","journal-title":"Syst Rev Pharm"},{"key":"756_CR10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/0250-474X.62237","volume":"72","author":"S Jose","year":"2010","unstructured":"Jose S, Dhanya K, Cinu TA, Aleykutty NA. Multiparticulate system for colon targeted delivery of ondansetron. Indian J Pharm Sci. 2010;72:58\u201364.","journal-title":"Indian J Pharm Sci"},{"key":"756_CR11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s13346-011-0016-4","volume":"1","author":"LFA Asghar","year":"2011","unstructured":"Asghar LFA, Chandran S. Design and evaluation of matrix base with sigmoidal release profile for colon-specific delivery using a combination of Eudragit and non-ionic cellulose ether polymers. Drug Deliv Transl Res. 2011;1:132\u201346.","journal-title":"Drug Deliv Transl Res"},{"key":"756_CR12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s13346-017-0358-7","volume":"7","author":"MM Patel","year":"2017","unstructured":"Patel MM. Formulation and development of di-dependent microparticulate system for colon-specific drug delivery. Drug Deliv Transl Res. 2017;7:312\u201324.","journal-title":"Drug Deliv Transl Res"},{"key":"756_CR13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0378-5173(96)04604-2","volume":"140","author":"B Abrahamsson","year":"1996","unstructured":"Abrahamsson B, Alpsten M, Jonsson UE, Lundberg PJ, Sandberg A, Sundgren M, et al. Gastro-intestinal transit of a multiple-unit formulation (metoprolol CR\/ZOK) and a non-disintegrating tablet with the emphasis on colon. Int J Pharm. 1996;140:229\u201335.","journal-title":"Int J Pharm"},{"key":"756_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpharm.2011.08.006","volume":"420","author":"FJO Varum","year":"2011","unstructured":"Varum FJO, Veiga F, Sousa JS, Basit AW. Mucoadhesive platforms for targeted delivery to the colon. Int J Pharm. 2011;420:11\u20139.","journal-title":"Int J Pharm"},{"key":"756_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0169-409X(00)00120-4","volume":"47","author":"H Takeuchi","year":"2001","unstructured":"Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev. 2001;47:39\u201354.","journal-title":"Adv Drug Deliv Rev"},{"key":"756_CR16","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.progpolymsci.2014.07.010","volume":"39","author":"A Sosnik","year":"2014","unstructured":"Sosnik A, Das Neves J, Sarmento B. Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review. Prog Polym Sci. 2014;39:2030\u201375.","journal-title":"Prog Polym Sci"},{"key":"756_CR17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0168-3659(94)00087-B","volume":"33","author":"A De Ascentiis","year":"1995","unstructured":"De Ascentiis A, deGrazia JL, Bowman CN, Colombo P, Peppas NA. Mucoadhesion of poly(2-hydroxyethyl methacrylate) is improved when linear poly(ethylene oxide) chains are added to the polymer network. J Control Release. 1995;33:197\u2013201.","journal-title":"J Control Release"},{"key":"756_CR18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejpb.2013.11.009","volume":"86","author":"T Pengpong","year":"2014","unstructured":"Pengpong T, Sangvanich P, Sirilertmukul K, Muangsin N. Design, synthesis and in vitro evaluation of mucoadhesive p-coumarate-thiolated-chitosan as a hydrophobic drug carriers. Eur J Pharm Biopharm. 2014;86:487\u201397.","journal-title":"Eur J Pharm Biopharm"},{"key":"756_CR19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijpharm.2012.05.076","volume":"434","author":"QR Cao","year":"2012","unstructured":"Cao QR, Liu Y, Xu WJ, Lee BJ, Yang M, Cui JH. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique. Int J Pharm. 2012;434:325\u201333.","journal-title":"Int J Pharm"},{"key":"756_CR20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejpb.2012.02.011","volume":"81","author":"T Bautzov\u00e1","year":"2012","unstructured":"Bautzov\u00e1 T, Rabi\u0161kov\u00e1 M, B\u00e9duneau A, Pellequer Y, Lamprecht A. Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis. Eur J Pharm Biopharm. 2012;81:379\u201385.","journal-title":"Eur J Pharm Biopharm"},{"key":"756_CR21","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3109\/03639049809097271","volume":"24","author":"C Li","year":"1998","unstructured":"Li C, Bhatt PP, Johnston TP. Evaluation of a mucoadhesive buccal patch for delivery of peptides: in vitro screening of bioadhesion. Drug Dev Ind Pharm. 1998;24:919\u201326.","journal-title":"Drug Dev Ind Pharm"},{"key":"756_CR22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jsps.2014.10.001","volume":"24","author":"Nidhi","year":"2016","unstructured":"Nidhi, Rashid M, Kaur V, Hallan SS, Sharma S, Mishra N. Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: a brief review. Saudi Pharm J. 2016;24:458\u201372.","journal-title":"Saudi Pharm J"},{"key":"756_CR23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0378-5173(98)00027-1","volume":"166","author":"P He","year":"1998","unstructured":"He P, Davis SS, Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm. 1998;166:75\u201388.","journal-title":"Int J Pharm"},{"key":"756_CR24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.12693\/APhysPolA.129.531","volume":"129","author":"DS Senturk","year":"2016","unstructured":"Senturk DS. Size dependent properties of hollow gold nanoparticles: a theoretical investigation. Acta Phys Pol A. 2016;129:531\u20134.","journal-title":"Acta Phys Pol A"},{"key":"756_CR25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1081\/DDC-100101266","volume":"26","author":"MZI Khan","year":"2000","unstructured":"Khan MZI, \u0160tedul HP, Kurjakovi\u0107 N. A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit\u00ae L100 and Eudragit S100 combinations. Drug Dev Ind Pharm. 2000;26:549\u201354.","journal-title":"Drug Dev Ind Pharm"},{"key":"756_CR26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijpharm.2014.04.040","volume":"468","author":"M Xu","year":"2014","unstructured":"Xu M, Sun M, Qiao H, Ping Q, Elamin ES. Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid. Int J Pharm. 2014;468:165\u201371.","journal-title":"Int J Pharm"},{"key":"756_CR27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1016208703380","volume":"12","author":"Y Akiyama","year":"1995","unstructured":"Akiyama Y, Nagahara N, Kashihara T, Hirai S, Toguchi H. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative. Pharm Res. 1995;12:397\u2013405.","journal-title":"Pharm Res"},{"key":"756_CR28","doi-asserted-by":"crossref","unstructured":"Dar MJ, Ali H, Khan A, Khan GM. Polymer-based drug delivery: the quest for local targeting of inflamed intestinal mucosa. J Drug Target. 2017:582\u201396.","DOI":"10.1080\/1061186X.2017.1298601"},{"key":"756_CR29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000336720","volume":"85","author":"T Ali","year":"2012","unstructured":"Ali T, Shakir F, Morton J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion. 2012;85:249\u201355.","journal-title":"Digestion."},{"key":"756_CR30","doi-asserted-by":"crossref","unstructured":"Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014:113\u201320.","DOI":"10.2147\/JIR.S65979"},{"key":"756_CR31","first-page":"141","volume":"14","author":"JS Jurenka","year":"2009","unstructured":"Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009;14:141\u201353.","journal-title":"Altern Med Rev"},{"key":"756_CR32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s13346-018-00598-8","volume":"9","author":"A Sesarman","year":"2019","unstructured":"Sesarman A, Tefas L, Sylvester B, Licarete E, Rauca V, Luput L, et al. Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment. Drug Deliv Transl Res. 2019;9:260\u201372.","journal-title":"Drug Deliv Transl Res"},{"key":"756_CR33","first-page":"1","volume":"5","author":"N Tirkey","year":"2005","unstructured":"Tirkey N, Kaur G, Vij G, Chopra K. Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol. 2005;5:1\u201310.","journal-title":"BMC Pharmacol"},{"key":"756_CR34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.powtec.2016.07.016","volume":"301","author":"H Rezaei","year":"2016","unstructured":"Rezaei H, Lim CJ, Lau A, Sokhansanj S. Size, shape and flow characterization of ground wood chip and ground wood pellet particles. Powder Technol. 2016;301:737\u201346.","journal-title":"Powder Technol"},{"key":"756_CR35","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1248\/cpb.48.420","volume":"48","author":"PWS Heng","year":"2000","unstructured":"Heng PWS, Wong TW, Chan LW. Influence of production variables on the sphericity of melt pellets. Chem Pharm Bull. 2000;48:420\u20134.","journal-title":"Chem Pharm Bull"},{"key":"756_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S1984-82502010000100002","volume":"46","author":"FC Carvalho","year":"2010","unstructured":"Carvalho FC, Bruschi ML, Evangelista RC, Gremi\u00e3o MPD. Mucoadhesive drug delivery systems. Braz J Pharm Sci. 2010;46:1\u201317.","journal-title":"Braz J Pharm Sci"},{"key":"756_CR37","doi-asserted-by":"crossref","unstructured":"Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001:571\u20137.","DOI":"10.1136\/gut.48.4.571"},{"key":"756_CR38","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1208\/s12249-015-0331-z","volume":"16","author":"SP Sawarkar","year":"2015","unstructured":"Sawarkar SP, Deshpande SG, Bajaj AN, Nikam VS. I n vivo evaluation of 5-ASA colon-specific tablets using experimental-induced colitis rat animal model. AAPS PharmSciTech. 2015;16:1445\u201354.","journal-title":"AAPS PharmSciTech"},{"key":"756_CR39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4292\/wjgpt.v8.i2.147","volume":"8","author":"S Kedia","year":"2017","unstructured":"Kedia S, Bhatia V, Thareja S, Garg S, Mouli VP, Bopanna S, et al. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: results from a randomized double blind placebo controlled trial. World J Gastrointest Pharmacol Ther. 2017;8:147.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"756_CR40","first-page":"206","volume":"5","author":"R Tiwari","year":"2013","unstructured":"Tiwari R, Agarwal SK, Tiwari S. Formulation and multivariate optimization of microcrystalline cellulose pellets of highly water soluble drug. Int J Drug Deliv. 2013;5:206\u201313.","journal-title":"Int J Drug Deliv"},{"key":"756_CR41","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/ma950981d","volume":"29","author":"T Inoue","year":"1996","unstructured":"Inoue T, Osaki K. Role of polymer chain flexibility on the viscoelasticity of amorphous polymers around the glass transition zone. Macromolecules. 1996;29:1595\u20139.","journal-title":"Macromolecules."},{"key":"756_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2329-6631.1000171","volume":"06","author":"H Baishya","year":"2017","unstructured":"Baishya H. Application of mathematical models in drug release kinetics of carbidopa and levodopa ER tablets. J Dev Drugs. 2017;06:1\u20138.","journal-title":"J Dev Drugs"},{"key":"756_CR43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/00365529850166914","volume":"33","author":"GM Ekstr\u00f6m","year":"1998","unstructured":"Ekstr\u00f6m GM. Oxazolone-induced colitis in rats: effects of budesonide, cyclosporin A, and 5-aminosalicylic acid. Scand J Gastroenterol. 1998;33:174\u20139.","journal-title":"Scand J Gastroenterol"},{"key":"756_CR44","doi-asserted-by":"crossref","first-page":"21127","DOI":"10.3390\/molecules191221127","volume":"19","author":"LV Brumatti","year":"2014","unstructured":"Brumatti LV, Marcuzzi A, Tricarico PM, Zanin V, Girardelli M, Bianco AM. Curcumin and inflammatory bowel disease: potential andlimits of innovative treatments. Molecules. 2014;19:21127\u201353.","journal-title":"Molecules."},{"key":"756_CR45","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0002-9149(99)00324-0","volume":"84","author":"M Feldman","year":"2013","unstructured":"Feldman M, Cryer B. The New England Journal of Medicine Downloaded from nejm.org at CASE WESTERN RESERVE UNIVERSITY on November 14, 2013. For personal use only. No other uses without permission. Copyright \u00a9 1994 Massachusetts Medical Society. All rights reserved. Am J Cardiol. 2013;84:404\u20139.","journal-title":"Am J Cardiol"},{"key":"756_CR46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00054725-199503000-00006","volume":"1","author":"WJ Sandborn","year":"1995","unstructured":"Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis. 1995;1:48\u201363.","journal-title":"Inflamm Bowel Dis"},{"key":"756_CR47","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0025-6196(12)60930-6","volume":"67","author":"W Sandborn","year":"1992","unstructured":"Sandborn W, Tremaine W. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc. 1992;67:981\u201390.","journal-title":"Mayo Clin Proc"},{"key":"756_CR48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0928-0987(94)00074-A","volume":"3","author":"MF Malmary","year":"1995","unstructured":"Malmary MF, Houti I, Labat C, Batalla A, Moussamih S, Bouguettaya D, et al. Chronopharmacokinetics of cyclosporine A following a single i.v. dose in the Wistar rat. Eur J Pharm Sci. 1995;3:49\u201356.","journal-title":"Eur J Pharm Sci"},{"key":"756_CR49","first-page":"103","volume":"7","author":"W Bachrach","year":"1955","unstructured":"Bachrach W. Medical treatment of ulcerative colitis. Clin Symp. 1955;7:103\u201318.","journal-title":"Clin Symp"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00756-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-020-00756-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00756-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T23:27:45Z","timestamp":1618010865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-020-00756-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1007\/s13346-020-00756-x","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,10]]},"assertion":[{"value":"10 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}